The effects of bolus injections of recombinant single-chain tissue-type plasminogen activator (rt-PA) and of F(ab')2 fragments of a murine monoclonal antibody (7E3) against the human platelet GPIIb/IIIa receptor [7E3-F(ab')2] on coronary arterial thrombolysis and reocclusion was studied in a canine preparation of coronary artery thrombosis superimposed on high-grade stenosis. Bolus intravenous injections of rt-PA at a dose of 0.45 mg/kg, repeated at 15 min intervals until reperfusion occurred (maximum of four injections) caused reperfusion in five of seven dogs within 100 min (33 -+-15 min, mean + SD). Reperfusion was rapidly followed (generally within 10 min) by reocclusion and then by periods of cyclical reflow and reocclusion. A single intravenous injection of 7E3-F(ab')2 alone at 0.8 mg/kg caused reperfusion within 100 min in two of six dogs (19 and 37 min) without subsequent reocclusion. Single bolus injections of different amounts (0.1 to 0.8 mg/kg) of 7E3-F(ab')2 were then combined with bolus injections of 0.45 mg/kg of rt-PA. Stable reperfusion without reocclusion was accomplished with 0.8 or 0.6 mg/kg 7E3-F(ab')2 and a single injection of 0.45 mg/kg rt-PA within 6 + 3 min (n=6, p<.01) and 8 + 5 min (n=5, p<.02), respectively. None of these animals suffered reocclusion of the coronary artery. Lower doses (0.1 to 0.2 mg/kg) of 7E3-F(ab')2 did not significantly shorten the time to reperfusion and did not prevent reocclusion. Combinations of intermediate doses [either 0.45 mg/kg rt-PA with 0.4 mg/kg 7E3-F(ab')2 or 0.225 mg/kg rt-PA with 0.6 mg/kg 7E3-F(ab')2] had an intermediate effect on the rate of reperfusion and the frequency of reocclusion. Bleeding times remained unchanged after injection of rt-PA alone and were moderately (about twofold) prolonged after the injection of 7E3-F(ab')2 at a dose of 0.1 to 0.4 mg/kg. With 0.6 mg/kg 7E3-F(ab')2 the bleeding time prolonged approximately four times and was greater than 30 min in four of nine dogs. At 0.8 mg/kg the bleeding time was consistently prolonged to more than 30 min; this dose blocked 83 -+ 5% of the GPIIb/IIIa receptors on the platelet surface. Thus, injection of F(ab')2 fragments of the monoclonal antibody 7E3, directed against the platelet GPIIb/IIIa receptor, accelerates thrombolysis with rt-PA and prevents reocclusion. Antagonists of the platelet GPIIb/IIIa receptor may constitute useful adjunctive therapy for coronary arterial thrombolysis in patients with acute myocardial infarction.
sion and/or the frequency of reocclusion may have significant clinical value.
We have developed a canine preparation of coronary artery thrombosis with superimposed high-grade stenosis for the investigation of the efficacy of thrombolytic agents,," both in terms of coronary arterial reperfusion and the prevention of reocclusion.12 In this preparation, in which the anatomic substrate (endothelial cell damage and high-grade stenosis) is similar to that in patients with acute myocardial infarction, thrombolysis achieved with a continuous infusion of a streptokinase, urokinase, or recombinant tissue-type plasminogen activator (rt-PA) is consistently followed by rapid reocclusion.'3 Reocclusion could, however, be prevented by pretreating the animals with a bolus injection of 0.8 mg/kg of the F(ab')2 fragment of the murine monoclonal antibody 7E3 [7E3-F(ab')2], which is directed against the platelet GPILb/IIIa receptor." ' 14 In the present study we investigated the effect of a single bolus injection of 7E3-F(ab')2 at various concentrations in combination with bolus injections of rt-PA on both the rate of coronary arterial thrombolysis and the frequency of reocclusion. Methods
Reagents. Single-chain rt-PA (G 11044) was supplied by Genentech Inc, South San Francisco, CA. 7E3-F(ab')2 were purified as previously described12 and were supplied by Centocor Inc. (Malvern, PA).
Dog coronary artery thrombolysis/reocclusion preparation. Coronary artery thrombosis and endothelial cell damage in association with controlled high-grade stenosis was produced in anesthetized open-chest dogs as described elsewhere.13 ' 15 In addition, superimposed high-grade stenosis was produced by the application of an external constrictor and blood flow was continuously monitored with an electromagnetic flow probe. Mongrel dogs weighing approximately 20 to 25 kg were anesthetized with intravenous sodium pentobarbital, intubated, and artificially ventilated. A left thoracotomy was performed and the internal mammary artery was cannulated for continuous blood pressure monitoring. Procainamide (1.5 g im) was given.
The left anterior descending coronary artery was dissected out from the epicardium, side branches were ligated, and a 1.5 cm segment was isolated. An electromagnetic flow probe (FM501, Carolina Medical Electronics, King, NC) was placed on the most proximal portion of the segment and intravenous lidocaine (15 mg bolus followed by a constant infusion at 1 mg/min) was given. A control left coronary angiogram was performed by the injection of approximately 2 ml of Renografin 76 by hand through a modified Judkin's No. 7F catheter inserted from a carotid artery. One milliliter ofblood was then removed and kept in a syringe for later use in forming the thrombus, and heparin (5000 units intravenous bolus) was administered. Additional 1000 unit boluses of heparin were administered at hourly intervals. A 2 mm wide-band constrictor was placed near the distal end of the segment and constricted to reduce coronary artery blood flow to 40 + 10% of control. High-resolution postmortem angiograms in selected animals showed that a constriction so placed decreased the luminal diameter by greater than 90%. The 1 cm of coronary artery just proximal to the constriction was then emptied of blood and isolated between temporary silk snares. Intimal damage was induced by grasping the segment with forceps and the segment was flushed by releasing the distal snare and injecting saline through a cannulated side branch. The segment was then reisolated and 0.1 ml of thrombin (Parke-Davis Topical Thrombin, 1000 U/ml, Morris Plains, NJ) and 0.3 ml of stored blood were injected into the isolated segment. After 5 min, first the proximal and then the distal ties were released and the side branch catheter was then removed, but the constrictor was left in place. Approximately 30 min after injection of the thrombin and blood, a repeat angiogram was performed to confirm the presence of complete coronary artery occlusion. The blood flow in the vessel was monitored continuously with the electromagnetic flow probe. If it indicated reperfusion, another angiogram was immediately performed. If not, control angiography was performed at 15 min intervals throughout the experiment. Infusion protocols. Four treatment groups were studied (table 1): 7E3-F(ab')2 alone at 0.8 mg/kg (group I), rt-PA alone at 0.45 mg/kg boluses (group II), combinations of variable doses of 7E3-F(ab')2 and 0.45 mg/kg boluses of rt-PA (group III), and a combination of 0.6 mg/kg of 7E3-F(ab')2 and 0.225 mg/kg boluses of rt-PA (group IV). Half of the animals in each group were selected during dose finding. The second half were assigned randomly. In groups I, III, and IV, 7E3-F(ab')2 was injected intravenously over 2 min, 30 min after thrombus formation. Ten minutes later rt-PA was injected in a bolus of 0.225 or 0.45 mg/kg over 2 min; repeat bolus injections were then given at 15 min intevals until reperfusion was achieved or a total of four doses had been given. In group II, bolus injections of rt-PA at 0.45 mg/kg were begun 30 min after thrombus formation. The reperfusion time was taken as the time from the first injection of rt-PA [or of 7E3-F(ab')2 in the controls not treated with rt-PA] until reperfusion was documented by both the return of blood flow in the coronary artery and angiographic confirmation of complete filling distal to the stenosis, with rapid clearance of dye within 4 heartbeats. No additional rt-PA was given in animals meeting this end point even if reocclusion followed. After reperfusion was accomplished, blood flow was monitored for evidence of reocclusion, with the final confirmation again by angiography with use of the same criteria as used for establishing reperfusion. The reocclusion time was taken as the interval between documented reperfusion and reocclusion. Dogs were observed for at least 100 min after the first rt-PA bolus injection in all but two experiments. Blood analysis. Venous blood samples for platelet and plasma assays were collected in 0.O1M citrate and 150 kallikrein inhibitor units (KIU) aprotinin/ml (Sigma, St. Louis). Platelet-rich plasma was prepared immediately and tested for ADP-induced platelet aggregation and 1251-7E3 binding as previously described. 1 Plasma was prepared from blood kept on ice until the end of the experiment, then centrifuged at room temperature and stored at -200 C. Fibrinogen was measured by a coagulation rate assay16 that is insensitive to therapeutic concentrations of heparin,17 and t-PA antigen was measured as previously described. 18 AMean + SD.
were then removed and immersion fixed in 5% buffered formaldehyde. The thrombosed, stenotic, and poststenotic segments of the left anterior descending coronary artery were then dissected and cross sectioned at 2 mm intervals, processed for light microscopy, and stained with hematoxylin and eosin.
Results
Infusion protocols. In all experimental groups, the constrictor reduced the blood flow to a mean value of approximately 40% of the baseline value (table 1) . Six dogs received a single bolus injection of 0.8 mg/kg 7E3-F(ab')2 and no rt-PA (group I). The number of rt-PA bolus injections in each group is shown in figure 1 . Seven dogs were given up to four boluses of 0.45 mg/kg rt-PA without antibody (group II). The median value for the number of boluses given at 15 min intervals required to obtain reperfusion was three, with a range of one to four. When rt-PA was given in conjunction with 0.8 or 0.6 mg/kg of 7E3-F(ab')2 (groups IlI-A and Il-B), only a single bolus of rt-PA was required to produce reperfusion in all dogs. Lower doses of 7E3-F(ab')2 were less effective in reducing the number of rt-PA bolus injections required to obtain reperfusion (groups Ill-C, III-D, and III-E). The combination of 0.6 mg/kg 7E3-F(ab')2 with 0.225 mg/kg boluses of rt-PA (group IV) also did not consistently produce permanent reperfusion after the first rt-PA bolus.
Results of coronary artery reperfusion and reocclusion. Table 2 and figure 1 summarize the results. Injection of a single bolus of 0.8 mg/kg of 7E3-F(ab')2 (group I) caused reperfusion in two of six dogs after 19 and 37 min. In these animals reocclusion was not observed during an observation period of 100 min. Five of the seven dogs given rt-PA alone (group II) achieved reperfusion but this required a median of three bolus injec-672 tions, and the time to reperfusion averaged more than 30 min. All five reperfused dogs rapidly showed evidence of reoccluison (table 2) , which was then followed by cyclical periods of reperfusion and reocclusion, as illustrated in figure 1 . When 0.8 mg/kg of 7E3-F(ab')2 was given 10 min before a single bolus injection of 0.45 mg/kg of rt-PA (group IlI-A), reperfusion occurred in all animals, and thus was achieved significantly more rapidly than when rt-PA was given alone (6 + 3 vs 33 ± 15 min, p<.01). Moreover, reocclusion did not occur in any of these animals (figure 1). Similar results were obtained at 0.6 mg/kg of 7E3-F(ab')2 in combination with a single bolus of 0.45 mg/kg rt-PA (group III-B), although one of the five reperfused dogs showed a single brief period of reocclusion followed by stable reperfusion. Further dose reductions of 7E3-F(ab')2 to 0.4 mg/kg and below (groups I1l-C, III-D, and Ill-E), resulted in a progressive prolongation of the time to reperfusion (table 2) and an increase of the required number of rt-PA boluses. More importantly, at these reduced doses of antibody, reocclusion was consistently observed.
When 0.6 mg/kg 7E3-F(ab')2 was combined with bolus injections of 0.225 mg/kg instead of 0.45 mg/kg of rt-PA (group IV), rapid and persistant reperfusion was not consistently obtained with single boluses.
Hemostasis analyses. Bleeding times measured before injection of rt-PA or 7E3-F(ab')2 ranged between 2 and 6 min (table 3) , indicating no significant prolongation secondary to heparinization. Injections of rt-PA alone (group II) did not prolong the bleeding time, whereas 0.8 mg/kg 7E3-F(ab')2 markedly prolonged the bleeding time in all 10 dogs tested in groups I and 11-A, with eight animals having bleeding times greater than 30 min. The bleeding time was also prolonged in the dogs CIRCULATION given 0.6 mg/kg (groups III-B and IV), with four of the tion of 7E3-F(ab')2 persisted throughout the observanine dogs having bleeding times greater than 30 min. tion period. At lower doses of 7E3-F(ab')2(groups Ill-C, III-D, and 1251-7E3 antibody binding studies performed 2 hr Ill-E), the The data are the mean + SD of values of responsive animals, and the median and range are values for the total group. had been blocked by the 7E3-F(ab')2. After injection of 0.6 mg/kg, the corresponding value in the five dogs studied was 76 + 10%. Platelet counts obtained before and at the end of the experiment showed no significant change in the absence of 7E3-F(ab')2 (table 3). In the groups with 0.8 mg/kg 7E3-F(ab')2 (groups I and III-A), the platelet count decreased between 7.5% and 28% over the course of the experiment.
The rt-PA bolus injections of 0.45 mg/kg caused an increase of the plasma rt-PA levels to 29 16 ,ug/ml (n = 18) 1 min after each injection; this level decreased to 0.5 + 0.7 ,ug/ml (n = 17) toward the end of the 100 min observation period. Fibrinogen levels decreased by an average of 25% after one bolus injection of rt-PA (n = 8), and by 67% after four boluses (n = 8; table 3). This indicates that significant fibrinogen breakdown occurred after a single bolus injection of 0.45 mg/kg. ADP-induced platelet aggregation studies, performed on blood obtained before and 30 min after antibody injection, showed a dose-related decrease in the initial figure 2, B) .
Pathologic examination. Typically, in animals given 7E3-F(ab')2, in which there was no reperfusion, the original clot was visualized extending into the stenotic zone. All animals reoccluded after bolus injections of rt-PA alone, and fibrin and platelet-rich thrombotic material were revealed in the stenotic region ( figure 3 ). Animals given the combination of 0.8 mg/kg antibody and rt-PA showed persistant reperfusion, as confirmed by the absence of occlusive thrombotic material in both the prestenotic and stenotic segments.
Discussion
Thrombolytic therapy with rt-PA holds promise for improving the morbidity and mortality of coronary Results represent a comparison of the values obtained 30 min after antibody (or rt-PA in group II) with those obtained before administration of antibody or rt-PA. T = change in light transmission. artery thrombosis, but several problems remain to be solved. In particular, the current method of administration requires continuous infusion of large doses,6-8 the time to reperfusion is usually greater than 45 min 6-8 reocclusion after thrombolysis occurs frequently (in approximately 25% of patients),8andthe risk of hemorrhage is higher than desirable.8 10 To address these shortcomings, we have embarked on a series of studies in a dog preparation with anatomic features similar to those occurring in patients with acute myocardial infarction, i.e., coronary artery thrombosis in the presence of high-grade stenosis. One of our approaches consists of thrombolysis with rt-PA and heparin in combination with a murine monoclonal antibody against the platelet GPI1b/ILIa receptor (7E3). The rationale for this combination rests on a expanding body of data: (1) thrombi are composed of platelets and fibrin in various combinations, and consequently inhibition of both contributing components may have additive or synergistic effects on thrombus formation and/or dissolution, (2) thrombi that reocclude coronary arteries after successful thrombolysis with rt-PA in the presence of heparin are rich in platelets,13 (3) blockade of the platelet GPIIb/I11a receptor with 7E3 results in profound inhibition of platelet aggregation by the agonists thought to operate in vivo (ADP, collagen, epinephrine, thrombin, and thromboxane A2),19 (4) selective blockade of GPI1b/ILIa receptors may diminish the number of platelets incorporated in the clot, resulting in diminished fibrin deposition and release of the platelet inhibitor of plasminogen activator. 20 In the present study we investigated the effect of 7E3-F(ab ')2 on the rate of coronary artery thrombolysis and the frequency of reocclusion after successful reperfusion with bolus injections of rt-PA.
Vol. 77, No. 3, March 1988 When 7E3-F(ab')2 was given alone at a concentration that nearly saturated the platelet surface GPI1b/IIIa receptors, reperfusion occurred in two of six dogs and neither dog reoccluded. This is in agreement with our previous observations in which this dose caused reperfusion within 10 min in two of 13 dogs.12 It suggests that coronary thrombi may be in a relatively dynamic state, with ongoing lysis by endogenous t-PA and continual accretion of platelets and fibrin. The relatively low frequency of reperfusion, however, indicates that the antibody alone is inadequate to secure consistent reperfusion. The use of the F(ab')2 antiplatelet antibody fragments did not lead to major removal of platelets by the spleen via the recognition of the FC portion of the immunoglobulin molecule, as shown by the stable platelet counts in group I (table 3) .
When rt-PA was given alone in up to four boluses of 0.45 mg/kg at 15 min intervals, reperfusion occurred within 33 ± 15 min in five of seven dogs. Rapid reocclusion occurred in all of these dogs, after which there were unstable periods of cyclical reocclusion and reperfusion. These results are similar to those obtained with a continuous infusion of an equivalent dose of rt-PA (30 pg/kg/min for 60 min).'3 Thus, in this preparation, with its intense thrombogenic stimulus at the site of a severe coronary artery stenosis, intermittent rt-PA bolus injection appears to have no practical advantage with respect to efficacy or speed of coronary artery reperfusion. In addition, the repeated bolus injections of rt-PA were associated with considerable A. systemic fibrinogen degradation (drop in fibrinogen to 75% of the preinfusion value after a single dose, and to 33% after four boluses). This is a far more pronounced effect than has been observed during continuous infusion of an equivalent dose of rt-PA over 1 hri9 11, 12 It is possible that the transiently high plasma level of rt-PA reached after bolus injection (up to 50 Ag/ml) produced some systemic plasmin-mediated fibrinogen degradation, exposing COOH-terminal lysine residues in the degraded molecules.21 This could trigger a positive feedback mechanism by offering sites to which plasminogen can bind and thus become more sensitive to conversion to plasmin.21 rt-PA has also been shown to promote platelet disaggregation when added to human platelet aggregates formed in vitro in plasma,22 but did not alter the aggregation curves in vivo in this study. In contrast to the use of 7E3-F(ab')2 or rt-PA alone, the combination of 0.8 mg/kg of 7E3-F(ab')2 and a single bolus injection of 0.45 mg/kg rt-PA was highly effective. Not only did thrombolysis consistently occur at a lower total dose of rt-PA, but it also occurred much more rapidly. Moreover, reocclusion in this group was prevented. Reperfusion after 0.8 mg/kg of platelet antibody and bolus rt-PA administration was more rapid than previously noted after antibody and continuous rt-PA administration in the same total dose.'2 This infusion scheme was associated with extensive blockade of platelet GPIIb/IIIa receptors, nearly total abolition of ADP-induced platelet aggregation, and marked prolongation of the bleeding time. Nevertheless, major bleeding from the surgical wounds was not noticed, although significant oozing was common. The clinical relevance of this gross observation is uncertain.
The 7E3-F(ab')2 dose-response data indicate that 676 prevention of reocclusion requires extensive inhibition of platelet function. The combination of 0.6 mg/kg 7E3-F(ab')2 with 0.225 mg/kg rt-PA was also only partially effective, indicating that acceleration of lysis occurs within a narrow concentration range for each of the agents.
The mechanism of the marked accelerating effect of 7E3-F(ab')2 on the rate of thrombolysis by rt-PA is not evident. Direct triggering of a fibrinolytic pathway by the binding of the antibody to the platelet receptor is not likely. Possibly its mechanism of action is via the inhibition of the accretion of platelets on the thrombus surface, where release of fibrinolytic inhibitors20 from the platelets might delay the fibrinolytic process. Alternatively, incorporation of functionally intact platelets may constitute a significant pathway in the dynamic equilibrium between thrombosis and thrombolysis leading to thrombus stabilization. Inhibition of platelets with 7E3-F(ab')2 would then displace this equilibrium toward thrombolysis. A further dose reduction to 0.4 mg/kg induced much less prolongation of the bleeding time and was associated with a tendency to reocclusion, although this dose still had an accelerating effect on thrombolysis with rt-PA. Thus, a dissociation between the effects of 7E3-F(ab')2 on coronary artery reperfusion and reocclusion on the one hand. and on the bleeding time on the other, was only observed above 0.2 mg/kg and below 0.6 mg/kg of 7E3-F(ab')2. From these data it appears that optimization of the combined use of rt-PA and 7E3-F(ab')2 will require careful dose titration of both agents to obtain optimal risk/benefit ratios in man.
The present study demonstrates that the combination of a potent selective thrombolytic agent with a potent selective platelet GPIIb/IIIa receptor-blocking agent CIRCULATION may accelerate coronary artery thrombolysis after a single bolus injection of rt-PA and abolish coronary artery reocclusion. In view of the significant clinical value of rapid reperfusion and prevention of reocclusion of coronary arteries in patients with acute myocardial infarction, 7E3-F(ab')2 or alternative agents interfering with the GPI1b/IILa receptor-mediated pathway of platelet activation may constitute useful adjunctive agents to thrombolytic therapy. The safety and efficacy of such combined therapy for coronary artery thrombolysis in man remains to be investigated. We thank Missy Stanton for outstanding secretarial support.
